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Objective: Biochemical assessment is recommended for patients prior to initiating and 
following a ketogenic diet (KD). There is no published literature regarding current practice in 
the UK and Ireland. We aimed to explore practice in comparison to international guidelines, 
determine approximate costs of biochemical testing in KD patients across the UK and 
Ireland, and promote greater consistency in KD services nationally. 
Methods:  A survey was designed to determine the biochemical tests requested for patients 
at baseline, 3-, 6-, 12-, 18- and 24-months+ on KD. The survey was circulated to 39 centres 
across the UK and Ireland.   
Results:  16 centres completed the survey. Full blood count, electrolytes, calcium, liver 
function tests (LFTs), lipid profile and vitamin D were requested at all centres at baseline, in 
keeping with international guidelines. Bicarbonate, total protein and urinalysis were less 
consistently requested. Magnesium and zinc were requested by all centres, despite not 
being specifically recommended for pre-diet evaluation in guidelines.  
Urea and electrolyte profiles and some LFTs were consistently requested at follow-up, in 
accordance with guidelines. Other LFTs and renal tests, full blood count, lipid profile, 
acylcarnitine profile, selenium, vitamin D and urinalysis were less consistently requested at 
follow-up. 
The mean costs of the lowest and highest number of tests requested at baseline in our 
participating centres was £167.54 and £501.93; the mean costs of the lowest and highest 
number of tests requested at 3-month follow-up was £19.17 and £450.06. 
Significance: Biochemical monitoring of KD patients varies widely across the UK and Ireland 
and does not fully correspond to international best practice guidelines. With an ongoing 
drive for cost-effectiveness within healthcare, further work is needed to streamline practice 
whilst ensuring patient safety. 
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Key points 
• Baseline tests are mostly in keeping with international guidelines, except for the 
addition of magnesium and zinc 
• Not all tests were not consistently requested by all centres at follow-up, despite 
recommendations 
• Mean costs of baseline tests ranged from £167.54-£501.93 
• Mean costs of 3-month follow-up tests ranged from £19.17-£450.06  
Introduction 
Ketogenic diets (KDs) are high-fat, low-carbohydrate, moderate protein diets used as a 
treatment option for drug-resistant epilepsy. KDs are the treatment of choice for 
neurometabolic disorders such as glucose transport type 1 deficiency syndrome1 and 
pyruvate dehydrogenase deficiency2, and are effective in reducing seizure frequency in 
approximately one third of patients with epilepsy3.  
KDs are inappropriate for some individuals, for example, with primary carnitine deficiencies 
and β-oxidation defects and thus screening biochemical tests to rule out such disorders are 
a crucial part of pre-diet assessment. KDs cause the body’s metabolism to adjust, utilising 
ketone bodies rather than glucose as its primary energy source. Due to stringent dietary 
restriction, individuals following a KD are often at risk of vitamin and mineral deficiencies4,5 
and therefore close biochemical monitoring is required to ensure nutritional adequacy and 
safety.  
International consensus guidelines regarding optimal care of paediatric patients on KD 
therapies have been recently updated, including which biochemical tests (blood and urine) 
should be completed prior to diet initiation and during the treatment period6. These follow 
on from KD care guidelines for resource-limited countries published in 2015, including 
required and desired biochemical monitoring7.  
Over the past two decades, the number of KD services in the UK and Ireland has increased 
from 22 to 39, with a concomitant surge in the number of patients on diet (from 101 in 
20008 to 754 in 20179. Centres in the UK and Ireland have local guidance for biochemical 
assessment and monitoring for KD patients but, to date, there has been no comparison nor 
consolidation of existing practices. Many of the biochemical tests required during KD 
treatment must be sent to specialist centres, further inflating costs and delays to treatment, 
conflicting with the current climate of the National Health Service (NHS), where services aim 
to be clinically and cost-effective. The 2018 international recommendations involved a high 
proportion of non-UK healthcare professionals from countries where costs are paid by 
insurance or by the patient privately, which could lead to disparities in practice.   
We aimed to i) explore current practice of biochemical testing in KD patients across the UK 
and Ireland in comparison to international guidelines, ii) determine approximate costs of 
biochemical testing in KD patients across the UK and Ireland, and iii) promote greater 
consistency in KD services nationally. To our knowledge, this is the first investigation of its 
kind. It is hoped that this work will help determine adherence to guidelines with regards 
biochemical monitoring of patients with epilepsy following a KD in the UK and Ireland, and 




A survey was designed by the Ketogenic Dietitians Research Network (KDRN) (a consortium 
of KD Healthcare Professionals) to identify biochemical tests requested in patients 
commencing and following a KD for epilepsy and metabolic disorders in centres in the UK 
and Ireland. The ketogenic dietitians at each centre were asked to list all biochemical 
investigations requested at baseline (pre-diet), 3-, 6-, 12-, 18- and 24-months post diet 
initiation during routine follow up (and other time points if applicable), as well as the 
frequency of biochemical follow-up for patients on diet longer than two years (the point at 
which, routinely, patients and medical teams may consider discontinuing the diet). Centres 
were also invited to share the cost of each biochemical test requested as part of their KD 
service, if available, which provided an indication of the financial range anticipated for tests 
at both baseline and review.  
The survey was disseminated via email to 39 services in the UK and Ireland. Following the 
initial email, two follow-up emails were sent in an attempt to obtain more responses. All 
answers were pseudo-anonymised and results were compared to the laboratory 
assessments recommended in international best practice guidelines6, as outlined in Table 1.  
Results 
16 centres completed the survey: 15 paediatric centres (of which 14 were NHS) and one 
non-NHS joint adult and paediatric centre.  
The number of patients referred annually for KD treatment in each of these centres, the 
patient population (paediatrics or adults), and the type of centre (primary, secondary or 
tertiary care) are outlined in Table 2.   
Current practice and comparison to international guidelines 
A total of 63 different biochemical tests were requested across the participating centres. 
Table 3 outlines recommended tests, clustered into clinical groups, and lists which groups of 
tests were requested by all, by 90-99%, by 75-90%, by 50-75% and then by <50% of 
participating centres. A list of all tests (ungrouped) and the percentage of centres that 
requested each test at each time point can be found in the Supplementary Table. 
Baseline monitoring 
Full blood count, electrolytes, calcium, liver function tests (LFTs), lipid profile and vitamin D  
were requested at all centres at baseline, in keeping with international guidelines (Table 3). 
Bicarbonate, total protein and urinalysis are recommended in international guidelines but 
were not consistently requested by our participating centres. Magnesium and zinc were also 
requested by all centres, despite not being specifically mentioned for pre-diet evaluation in 
international guidelines.  
Follow-up monitoring  
Twelve centres requested biochemical tests routinely at 3-, 6-, 12-, 18- and 24-months post-
diet initiation; two centres did not request any tests at 3 months, one centre that did not 
request any tests at 18 months, and one centre requested tests at 3-months and then 6-
monthly thereafter (testing requested at 3-,9-, 15-months post-diet initiation).  
Urea, creatinine and electrolytes, alanine aminotransferase (ALT) and alkaline phosphatase 
(ALP) were requested by all centres at 3-, 6-, 12-, 18-and 24-month follow-up (centres that 
routinely requested biochemical tests at these respective time points). Full blood count, 
lipid profile and albumin were requested by each of our centres at every review except for 
the 18-month point. Other components of renal profile and liver function tests, acylcarnitine 
profile, selenium, vitamin D and urinalysis were less consistently requested at follow-up 
(Table 3). 
13/16 (81%) centres requested non-fasting lipid profiles, both at baseline and review, 
despite recommendations for a fasting lipid profile. Seven of these 13 requested non-fasting 
lipid profiles, but would repeat in a fasted state if initial results were abnormal.   
 Long-term follow-up 
For those centres following patients up for more than 2 years: 10/16 (63%) centres 
requested 6-monthly monitoring for patients following a KD , in keeping with guidelines 
advising six-monthly visits after following a KD for 1 year. 5/16 (33%) centres requested 
yearly monitoring and 1/16 (6%) had no protocol. 
 
Cost implications 
The mean costs of the lowest and highest number of tests requested at baseline in our 
participating centres was £167.54 and £501.93; the mean costs of the lowest and highest 
number of tests requested at 3-month follow-up was £19.17 and £450.06. For comparison, 
the mean cost per visit of all biochemical tests recommended in international guidelines was 
£108.96 at baseline and £126.09 at review. The minimum, maximum and mean cost per test 
can be found in Table 4.  
 
Discussion 
Our study illustrates that biochemical assessment and monitoring of KD patients with 
epilepsy vary widely across the UK and Ireland and do not fully correspond to international 
best practice guidelines6. This variability is reflected in the associated costs of biochemistry 
testing. To our knowledge, there are no other previously published works outlining which 
biochemical tests are requested in KD patients in the UK and Ireland and their financial 
impact. 
Variability of practice is inevitable, due to differing patient populations in each centre and 
the acute needs of individuals, particularly in the complex cohort that commence dietary 
therapy for refractory epilepsy. However, the level of variability amongst our participating 
centres seems striking. This may be partially explained by the fact that the expansion of KD 
services in the UK and Ireland is a recent and somewhat sporadic phenomenon9,10. Only in 
recent years have technological advances and the creation of national groups, such as 
KDRN, facilitated liaison across participatory centres, promoting communication and sharing 
of resources. Research study protocols, such as those from the original randomised 
controlled trial at Great Ormond Street11 and Ketogenic Diet in Infants with Epilepsy 
(KIWE)12 may also influence what tests are requested at participating centres.  
Our costing results, although approximate, indicate that biochemical testing for KD patients 
can have a substantial financial impact on services, as well as highlighting the variability 
between centres. The final cost to an individual centre will vary, as large teaching hospitals 
can often benefit from lower costings due to higher workload and are more likely to have 
specialist tests available on site. Between hospital laboratories, the items included in a 
profile vary. In addition, the type of technology used (for example, high throughput minimal 
intervention automated analysers versus mass spectrometry for 25-hydroxy vitamin D3) 
and, in some cases, the interpretation of the laboratory price list can also impact the final 
cost: some centres may ask for the cost to measure a set of electrolytes, liver function tests 
and a bone profile, whereas asking for a ‘full profile’ should cost slightly less due to the 
overlap in tests. Notwithstanding these caveats, a difference of £334.39 between minimum 
and maximum requested baseline tests and £430.89 for 3-month review tests in our 
participating centres is noteworthy.  
Any ‘lesser’ costs in KD laboratory monitoring need to be balanced against the possible 
increased risk of complications, with associated costs. Even the cost of ‘complete’ KD 
monitoring may be less than treatment with a new antiepileptic drug, which can cost up to 
approximately £100/month13, as well as the costs implicated in seizure-related 
complications. On the other hand, it may not be appropriate to test for each recommended 
parameter at every review, such as vitamin D, due to the time taken for changes to take 
effect14,15. 
Magnesium and zinc were requested by all our participating centres at baseline, despite not 
being included in international best practice guidelines for pre-diet evaluation. This may 
represent a cost saving if unnecessary in most patients. No report of zinc deficiencies in 
individuals following a KD have been identified, although classical KDs with a 2:1 ratio or 
higher fail to meet the dietary reference intake for zinc, despite ‘selection of nutrient dense 
foods’16. One may argue that if mentioned as ‘optional’ to measure at review, as in 
international guidelines, baseline assessment of zinc would also be appropriate. Mean 
plasma magnesium levels have been found to decrease in children on the classical KD4 and 
the diet has been shown to provide suboptimal magnesium levels16. Intakes of zinc and 
magnesium may be suboptimal even prior to KD initiation: 3-27% and 0-50% of the UK 
population surveyed in the latest National Diet and Nutrition Survey (including males and 
females across all age groups above 1.5years) do not meet the lower reference nutrient 
intake (RNI) for zinc and magnesium respectively17. 
The discrepancies between which tests were requested at all review appointments in our 
centres compared to international recommendations may be predominantly cost-driven, 
particularly considering that the 2018 guidelines involved a high proportion of non-UK 
healthcare professionals from countries where costs are paid by insurance or by the patient 
privately, compared to the government-funded UK National Health Service, which could 
potentially be considered ‘resource-limited’. Furthermore, whilst NICE recommends KDs for 
paediatric refractory epilepsy18, it does not suggest recommendations for monitoring and so 
there is no UK cost-effective reference guidelines. In previous guidelines issued for resource-
limited regions, bicarbonate was deemed mandatory at baseline and review, and urinalysis 
and lipid profile were mandatory at review7.  
Published reports of abnormalities in individuals following KDs may provide guidance as to 
whether it is necessary to request the ‘missing’ parameters at each review in UK and Ireland 
centres. Besides dyslipidaemia, which is one of the most well-cited (although often 
transient) biochemical side effects of KDs, occurring in approximately 12% of children 
studied prospectively on a KD19, reports of abnormalities of other parameters are 
uncommon. Individuals following a KD have been shown to have reduced serum 25-
hydroxyvitamin D concentration (as were individuals solely on antiepileptic drugs) and 
reduced bone mass (to a greater extent than in individuals solely on drug therapy)20; 
another study found 25-hydroxyvitamin D levels (which were mostly low at diet initiation) to 
improve initially on commencement of a KD, including supplementation, but to decline after 
three months21. Selenium deficiency has been reported in 66 individuals on KD treatment22-
25, associated with cardiomyopathy in two of these patients23,25 and sudden cardiac death in 
another two24. A trend of decreasing plasma selenium was noted in participants of the 
original randomised controlled trial at GOSH, with a significant decrease between baseline 
and six months in children on the classical KD, although mean plasma selenium was 
maintained within the GOSH reference ranges4.  
In view of the possible association of selenium with cardiac abnormalities, monitoring of 
selenium seems significant, although prolonged QT interval has also been reported in three 
cases following a KD in the absence of selenium deficiency26. The frequency of testing at 
review, particularly in the 12-24-month follow-up period, may need revisiting specifically for 
the UK and Ireland in order to balance clinical safety with the potential financial/logistical 
constraints of 6-monthly testing.  
This study has several limitations. Only 16 of the 39 centres that (to our knowledge) practice 
KDs within the UK and Ireland volunteered to answer the survey; practice in the other 
centres remains unknown. The survey was not validated and could be subject to reporter 
error. Our cost estimations would also improve in accuracy with greater centre 
participation.  A follow-up study to assess whether rate of complications is correlated with 
frequency and ‘completeness’ of laboratory monitoring would be pertinent. 
Biochemical monitoring of KD patients varies widely across the UK and Ireland and does not 
fully correspond to international best practice guidelines. With an ongoing drive for cost-
effectiveness within the NHS, further work is needed to streamline practice whilst ensuring 
patient safety, both for financial benefit without clinical compromise for patients, perhaps 
with the creation of nationwide-specific guidelines. Further research into biochemical 
monitoring of KDs worldwide would be of interest to compare to practice in the UK and 
Ireland. 
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